NC-DOLE
19.1.2022 18:59:12 CET | Business Wire | Press release
The American-Costa Rican Chamber of Commerce (AmCham) recognized Dole through its daughter company, Standard Fruit Company de Costa Rica S.A., with the Social Responsibility in Action Award in the Employees Category for their project "De la Mano con Dole" — which loosely translates to "Hand-in-Hand with Dole". This year marks the 25th anniversary of the award which was given December 8, 2021.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220119005875/en/
The Hand-in-Hand with Dole project is an initiative that works towards positively impacting the social development of Standard Fruit Company of Costa Rica (aka Dole Costa Rica) employees and their families, using the Business Multidimensional Business Index (bMPI) methodology developed by the University of Oxford.
The bMPI methodology seeks to measure poverty—not only from the traditional way of per capita income —but also by incorporating dimensions such as, access to health, education, housing, work, social protection and 16 other key indicators. This allows the organization to identify gaps in social programs and work towards solving the multidimensional poverty issues confronted by their employees and their relatives.
Dole is the first agribusiness company in the world to apply the bMPI methodology to address the challenges of social development.
During the diagnostic stage of implementation, Dole Costa Rica achieved a participation rate of 87% in response to socioeconomic surveys among its more than 5300 employees, ranking near the highest level of participation among the companies that have applied the method in the country.
Analysis of the discovered “deficiencies” refocused short-term priorities of the company towards the prevention of disease and the health of our employees at the onset of Covid, to longer term strategies of social protection and health. At the end of September 2021, 500 gaps had been closed.
“We are very proud of being the first banana and pineapple producer to implement this system and seeing such positive results for our employees and families here in Costa Rica,” said Mr. Renato Acuña, President of Dole Fresh Fruit Latin America. “The strategies developed in this program, including social counseling and community care projects, seek to meet needs and provide the necessary capacities for better human development.”
For this project, Dole management has prioritized addressing the following needs: people without health insurance; people with disabilities not receiving state assistance; older adults without a pension, people out of the workforce due to family obligations; and households without drinking water.
In applying findings, Dole has established strategic alliances with Horizonte Positivo, a local NGO that leads the implementation of bMPI in Costa Rica, and with Sophia Oxford, an international non-profit organization that seeks to impact the social investment of companies and the lives of their employees. These third-party interpretations and analyses of results, and the proposal of solutions that can positively affect the reduction of multidimensional poverty, are essential to best practices in solution implementation.
In 2020, Dole introduced its three-pillared Sustainability Framework, The Dole Way , and its ongoing commitment For Food, For Nature and For People. Just as Dole Costa Rica was a pioneer more than 20 years ago in the development of global environmental management systems in agriculture to frame its efforts 'For Nature'; at the beginning of this decade the company intends through this project, to innovate in the establishment of a social development platform focused on its most important resource: 'For People'."
About Dole
Dole plc is one of the world’s largest producers and marketers of high-quality fresh fruit and fresh vegetables. Dole is an industry leader in many of the products it sells, as well as in nutrition education and research. For more information, please visit www.dole.com or www.doleplc.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220119005875/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
